热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新数据显示，2月11日，上海睿郡资产管理有限公司增持时代天使（06699）67.34万股， 每股均价77.5624港元，总金额约为5223.05万港元。增持后最新持股数目为866.72万股，持股比例为 5.08%。 香港联交所最新数据显示，2月11日，上海睿郡资产管理有限公司增持时代天使（06699）67.34万股， 每股均价77.5624港元，总金额约为5223.05万港元。增持后最新持股数目为866.72万股，持股比例为 5.08%。 责任编辑：卢昱君 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 ...

| 股份代號: | 066990 | | --- | --- | | 上市法國名稱: | 時代天使科技有限公司 | | 日期 (日 / 月 / 年): | 12/01/2026 - 12/02/2026 | 格隆汇2月12日丨根据联交所最新权益披露资料显示，2026年2月11日，时代天使(06699.HK)获上海睿郡资产管理有限公司在场内以每股均价77.5624港元增 持67.34万股，涉资约5223.05万港元。 增持后，上海睿郡资产管理有限公司最新持股数目为866.72万股，持股比例由4.68%上升至5.08%。 | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | | | 原因 | 股份數目 | | ( 請參閱上述 * 註 有投票權股 (日 / 月 / 年) * | | | | | | | 館) | 份百分比 | | | | | | ( % | | | Company of the program and consis ...

智通财经APP获悉，香港联交所最新数据显示，2月11日，上海睿郡资产管理有限公司增持时代天使 (06699)67.34万股，每股均价77.5624港元，总金额约为5223.05万港元。增持后最新持股数目为866.72万 股，持股比例为5.08%。 ...

香港联交所最新数据显示，2月11日，上海睿郡资产管理有限公司增持时代天使(06699)67.34万股，每股 均价77.5624港元，总金额约为5223.05万港元。增持后最新持股数目为866.72万股，持股比例为5.08%。 ...

Core Viewpoint - Goldman Sachs increased its stake in Times Angel (06699) by purchasing 226,200 shares at an average price of HKD 72.15 per share, totaling approximately HKD 16.32 million, resulting in a new holding of about 10.32 million shares, representing 6.04% of the company [1] Group 1 - Goldman Sachs' purchase of 226,200 shares indicates a bullish sentiment towards Times Angel [1] - The average purchase price of HKD 72.15 per share reflects the current market valuation of Times Angel [1] - The total investment of approximately HKD 16.32 million signifies a significant commitment by Goldman Sachs to the company [1]

Group 1 - Goldman Sachs increased its stake in Times Angel (06699) by 226,200 shares at an average price of HKD 72.15 per share, totaling approximately HKD 16.32 million [1] - Following the increase, Goldman Sachs now holds approximately 10.3181 million shares, representing a holding percentage of 6.04% [1]

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: CDMO Sector - The company has a constructive outlook on CDMO enterprises due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - Ratings for WuXi AppTec (02359, 603259.SH) and WuXi Biologics (02268) have been upgraded to "Buy" [1] Group 2: Biotech and Pharmaceutical Companies - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing potential, along with actual transaction expectations [1] - Companies such as Kelun-Biotech (06990), Innovent Biologics (02696), and Hansoh Pharmaceutical (03692) are viewed positively [1] Group 3: Medical Devices Sector - The company maintains a neutral view on the medical devices sector, noting that while the industry has bottomed out, recovery will take time [1] - Recommendations include buying Angelalign Technology (06699) and Weigao Group (01066) [1] Group 4: Medical Services Sector - A relatively cautious stance is held regarding the medical services sector due to ongoing cost control measures and a weak consumer cycle [1] - The rating for Haijia Medical (06078) has been downgraded to "Neutral" [1]

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors needing to consider the value of more R&D pipelines when evaluating valuations [1] Group 1: Investment Strategy - Companies are now trading based on actual execution capabilities rather than solely on licensing deal expectations [1] - Achieving returns that exceed the industry will rely more on key data releases, actual transactions, and visibility on earnings realization or turning points [1] Group 2: Sector Insights - The outlook for CDMO companies is becoming more constructive due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - The ratings for WuXi AppTec and WuXi AppTec Holdings have been upgraded to "Buy" [1] Group 3: Selective Strategy in Biotech and Pharma - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing potential, along with actual transaction expectations [1] - Companies such as Kelun-Biotech, Junshi Biosciences, and Hansoh Pharmaceutical are viewed positively [1] Group 4: Medical Devices Sector - The medical devices sector is maintained with a neutral outlook, indicating that while the industry has bottomed out, recovery will take time [1] - Recommended stocks include Angelalign Technology and Weigao Group [1]

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: Investment Strategy - Companies are now trading based more on actual execution capabilities rather than solely on licensing deal expectations [1] - Achieving returns that exceed the industry average this year will rely more on key data releases, actual transactions, and visibility on profit realization or turning points [1] Group 2: Sector Analysis - The outlook for CDMO companies is becoming more constructive due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - The ratings for WuXi AppTec and WuXi AppTec Holdings have been upgraded to "Buy" [1] Group 3: Selective Strategy in Biotech and Pharma - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing some promise, along with actual transaction expectations [1] - Companies such as Kelun-Biotech, Innovent Biologics, and Hansoh Pharmaceutical are viewed positively [1] Group 4: Medical Devices Sector - The medical devices sector maintains a neutral outlook, as the industry has bottomed out but requires time for gradual recovery [1] - Recommendations include buying Angelalign Technology and Weigao Group [1]

Core Insights - The article highlights the top short-selling ratios and amounts for various companies, indicating significant market sentiment against these stocks [1][2]. Group 1: Top Short-Selling Ratios - Lenovo Group-R (80992) has the highest short-selling ratio at 91.38% with a short-selling amount of 52.16 thousand [2]. - Ping An Insurance-R (82318) follows with a short-selling ratio of 83.34% and a short-selling amount of 200.88 thousand [2]. - Xiaomi Group-WR (81810) has a short-selling ratio of 80.95% with a short-selling amount of 597.54 thousand [2]. Group 2: Top Short-Selling Amounts - Tencent Holdings (00700) leads in short-selling amount at 29.69 billion, with a short-selling ratio of 15.25% [2]. - Alibaba Group-W (09988) has a short-selling amount of 23.66 billion and a short-selling ratio of 19.56% [2]. - Xiaomi Group-W (01810) ranks third with a short-selling amount of 10.16 billion and a short-selling ratio of 21.54% [2]. Group 3: Top Short-Selling Deviation Values - Ping An Insurance-R (82318) has the highest deviation value at 36.33%, indicating a significant difference from its average short-selling ratio [2]. - Xiaomi Group-WR (81810) follows with a deviation value of 34.41% [2]. - China Resources Beer (00291) has a deviation value of 33.89% [2].